Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial.

Next Previous
Trial Profile

LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Tecemotide (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms LICC

    • Most Recent Events

    • 15 Apr 2022 Results Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3) assessing survival after secondary liver resection in metastatic colorectal cancerpublished in the International Journal of Cancer
    • 04 Jun 2019 Results of a comparative analysis assessing survival after secondary liver resection in metastatic colorectal cancer in LICC, FIRE-3 and CELIM, presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2019 Primary endpoint (Recurrence-free survival (RFS) time and 3 year overall survival (OS) time) has not been met, according to the results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top